“As a global thought leader in muscle and health, we have been working with Dr. Evans in both his academic and Pharmaceutical positions for years” said David Fineman, Chairman and CEO KineMed. “We are very excited that Bill has decided to become part of our leadership team. His impact will be substantial.”
William J. Evans Ph.D. is an Adjunct Professor of Medicine in the Geriatrics Program at the Duke University Medical Center in Durham, North Carolina and for the past four years was the Vice President and Head of the Muscle Metabolism Discovery Performance Unit at GlaxoSmithKline (GSK). This group is dedicated to developing new medicines to treat muscle wasting, frailty, and sarcopenia. Prior to GSK, he was the Jane and Ed Warmack Chair of Nutritional Longevity and director of the Nutrition, Metabolism, and Exercise Laboratory in the Donald Reynolds Institute on Aging at the University of Arkansas for Medical Sciences from 1997 to 2009. He was also the director of the Noll Physiological Research Center at the Pennsylvania State University and served as the Chief of the Human Physiology Laboratory at the U.S.D.A. Human Nutrition Research Center on Aging at Tufts University.
Dr. Evans is a Fellow of the American College of Sports Medicine, The American College of Nutrition, and an honorary member of the American Dietetic Association. He is the author or co-author of more than 250 publications in scientific journals with an H-index of 75 (75 publications cited more than 75 times). His research has examined the functional and metabolic consequences of physical activity in elderly people as well as dietary protein needs of older men and women. Along with Irwin Rosenberg, M.D., he is the author of Biomarkers: The Ten Determinants of Aging You Can Control (Simon & Schuster) and authored AstroFit (Simon & Schuster, 2002). His studies have demonstrated the ability of older men and women to improve strength, fitness, and health through exercise, even into the 10th decade of life. His work has been featured on CBS evening news, 20/20, Good Morning America, NOVA, the New York Times, and a variety of media outlets. In 2005, he was invited to testify before the Senate Special Committee on Aging on strategies to save Medicare through prevention of chronic diseases associated with aging.
About KineMed, Inc.
KineMed is a growing health technology company that has developed a proprietary biomarker platform technology with broad applications in drug development and medical diagnostics.
Using its patented technology, KineMed has developed analytic biomarker tests which measure, in a single sample, the rate of change of critical biological pathways. KineMed believes that its unique ability to measure the production and destruction of the key molecules involved in disease-modifying biological processes provides meaningful, and previously unavailable, information about both diseases and wellness, which can transform healthcare decisions. KineMed is expanding from its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests.
For more information about KineMed, please visit: www.kinemed.com